Home/Pipeline/Amylin Program

Amylin Program

Metabolic Disorders

DiscoveryActive

Key Facts

Indication

Metabolic Disorders

Phase

Discovery

Status

Active

Company

Orion Biotechnology

About Orion Biotechnology

Orion Biotechnology is a preclinical-stage biotech company developing first-in-class GPCR-targeted therapies for obesity and metabolic diseases. Its core asset is the PROcisionX™ platform, which integrates phage display, multiplex chemical synthesis, and structure-activity analysis to generate optimized drug candidates in under six months. The company is advancing two lead candidates against the novel target GPR75 towards clinical development, led by a seasoned management team with deep pharmaceutical industry experience.

View full company profile

Therapeutic Areas

Obesity Metabolic Disorders

Other Metabolic Disorders Drugs

Drug	Company	Phase	Status
Novel GLP-1 Receptor Agonist	lupin	Pre-clinical/Clinical	Licensed (Gan & Lee)
Undisclosed Metabolic Program	Kallyope	Discovery	Active
Metabolic Disorders Program	Seragon Biosciences	Pre-clinical	Active
PPARγ Program	Micar Innovation	Discovery	Active
Pancreas-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
IVL-001	InVirtuoLabs	Discovery	Active
AmorphOX GLP-1	Orexo	Preclinical	Active
Not specifically disclosed on public website	Taisho Pharmaceutical	Various	Active
TLC590	Taiwan Liposome Company	Phase 2	Active